Ultragenyx (RARE) - Net Assets
Based on the latest financial reports, Ultragenyx (RARE) has net assets worth $-229.00 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.30 Billion) and total liabilities ($1.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore RARE operating cash flow to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-229.00 Million |
| % of Total Assets | -17.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -107.91% |
| 10-Year Change | -115.4% |
| Growth Volatility | 198.25 |
Ultragenyx - Net Assets Trend (2011–2025)
This chart illustrates how Ultragenyx's net assets have evolved over time, based on quarterly financial data. Explore Ultragenyx long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Ultragenyx (2011–2025)
The table below shows the annual net assets of Ultragenyx from 2011 to 2025. For live valuation and market cap data, see Ultragenyx (RARE) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-73.00 Million | -127.83% |
| 2024-12-31 | $262.30 Million | -4.76% |
| 2023-12-31 | $275.41 Million | -21.87% |
| 2022-12-31 | $352.49 Million | -61.79% |
| 2021-12-31 | $922.56 Million | -20.08% |
| 2020-12-31 | $1.15 Billion | +76.57% |
| 2019-12-31 | $653.76 Million | +7.37% |
| 2018-12-31 | $608.91 Million | +58.80% |
| 2017-12-31 | $383.45 Million | -19.10% |
| 2016-12-31 | $473.97 Million | -10.75% |
| 2015-12-31 | $531.09 Million | +187.16% |
| 2014-12-31 | $184.94 Million | +269.09% |
| 2013-12-31 | $50.11 Million | -40.59% |
| 2012-12-31 | $84.34 Million | +692.45% |
| 2011-12-31 | $10.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ultragenyx's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 452384500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $9.00 Million | % |
| Other Components | $4.44 Billion | % |
| Total Equity | $-80.00 Million | 100.00% |
Ultragenyx Competitors by Market Cap
The table below lists competitors of Ultragenyx ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pandox AB (publ)
ST:PNDX-B
|
$2.30 Billion |
|
Yunnan Botanee Bio-Technology Group Co Ltd
SHE:300957
|
$2.31 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
$2.31 Billion |
|
TAV HAVALIMAN.HLDG ADR/4
F:5THA
|
$2.31 Billion |
|
Grupo Bafar S.A.B. de C.V
MX:BAFARB
|
$2.30 Billion |
|
Distribuidora Internacional de Alimentación S.A
MC:DIA
|
$2.30 Billion |
|
Kayne Anderson MLP Investment Closed Fund
NYSE:KYN
|
$2.30 Billion |
|
Zhejiang Daily Media Group Co Ltd
SHG:600633
|
$2.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ultragenyx's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 255,297,000 to -80,000,000, a change of -335,297,000 (-131.3%).
- Net loss of 575,000,000 reduced equity.
- New share issuances of 86,000,000 increased equity.
- Other comprehensive income increased equity by 9,643,000.
- Other factors increased equity by 144,060,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-575.00 Million | -718.75% |
| Share Issuances | $86.00 Million | +107.5% |
| Other Comprehensive Income | $9.64 Million | +12.05% |
| Other Changes | $144.06 Million | +180.08% |
| Total Change | $- | -131.34% |
Book Value vs Market Value Analysis
This analysis compares Ultragenyx's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.46 | $23.39 | x |
| 2012-12-31 | $3.66 | $23.39 | x |
| 2013-12-31 | $1.72 | $23.39 | x |
| 2014-12-31 | $6.43 | $23.39 | x |
| 2015-12-31 | $14.44 | $23.39 | x |
| 2016-12-31 | $11.97 | $23.39 | x |
| 2017-12-31 | $9.03 | $23.39 | x |
| 2018-12-31 | $12.23 | $23.39 | x |
| 2019-12-31 | $11.56 | $23.39 | x |
| 2020-12-31 | $18.97 | $23.39 | x |
| 2021-12-31 | $13.61 | $23.39 | x |
| 2022-12-31 | $5.04 | $23.39 | x |
| 2023-12-31 | $3.74 | $23.39 | x |
| 2024-12-31 | $2.82 | $23.39 | x |
| 2025-12-31 | $-0.81 | $23.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ultragenyx utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -85.44%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-76.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -64.35% | 0.00% | 0.00x | 1.14x | $-7.91 Million |
| 2012 | -19.37% | 0.00% | 0.00x | 1.05x | $-24.77 Million |
| 2013 | -69.99% | 0.00% | 0.00x | 1.19x | $-40.08 Million |
| 2014 | -32.34% | 0.00% | 0.00x | 1.07x | $-78.30 Million |
| 2015 | -27.42% | 0.00% | 0.00x | 1.05x | $-198.73 Million |
| 2016 | -51.87% | -184867.67% | 0.00x | 1.14x | $-293.27 Million |
| 2017 | -78.79% | -11567.34% | 0.01x | 1.28x | $-340.48 Million |
| 2018 | -32.45% | -383.75% | 0.07x | 1.18x | $-258.50 Million |
| 2019 | -61.60% | -388.31% | 0.09x | 1.74x | $-468.10 Million |
| 2020 | -16.16% | -68.84% | 0.15x | 1.52x | $-302.00 Million |
| 2021 | -49.21% | -129.20% | 0.23x | 1.65x | $-546.28 Million |
| 2022 | -200.69% | -194.71% | 0.24x | 4.38x | $-742.67 Million |
| 2023 | -220.26% | -139.70% | 0.29x | 5.41x | $-634.18 Million |
| 2024 | -222.95% | -101.60% | 0.37x | 5.89x | $-594.71 Million |
| 2025 | 0.00% | -85.44% | 0.44x | 0.00x | $-567.00 Million |
Industry Comparison
This section compares Ultragenyx's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ultragenyx (RARE) | $-229.00 Million | -64.35% | N/A | $2.30 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more